EU MDR 2017/745 Consulting Indiana

Taking your medical device to Europe opens the door to one of the largest healthcare markets in the world. EU MDR 2017/745 governs how medical devices enter and operate within the European market. For Indiana device developers who know the FDA system but face European rules for the first time, the path can feel unfamiliar. MedLaunch breaks down EU MDR requirements into straightforward stages, guiding your Indiana-built device to European patients.

This page explains what EU MDR 2017/745 means and the exact path to CE marking, plus how MedLaunch supports you at every stage.

What Is EU MDR 2017/745?

EU MDR 2017/745 is the European Union’s Medical Device Regulation. Before your device can carry the CE mark and reach European patients, it must meet strict safety, performance, and quality standards set by this regulation.

When the EU introduced MDR 2017/745, it replaced the older Medical Device Directive. The new regulation requires stronger clinical evidence, more comprehensive documentation, and continuous monitoring of devices after they enter the market. These changes reflect a commitment to patient safety across Europe.

Why Indiana Developers Need Specialized Support

Indiana holds a growing medical device community, from orthopedic and diagnostic firms to early-stage startups. Many local teams know FDA requirements well but have never worked through a European submission.

• Different system: EU MDR uses its own classification rules, documentation standards, and market representatives.
• High stakes: Without EU MDR compliance, you cannot legally sell your device in Europe.
• Time pressure: Investors and market windows push you to move quickly, yet EU MDR work takes careful planning.

FDA clearance does not carry over to Europe. You need a separate, EU-specific pathway, and that pathway starts with EU MDR. We help you map what you already have to what Europe expects.

How Does EU MDR Change Device Classification?

Classification decides how much scrutiny your device faces. Under EU MDR, many devices moved into higher risk classes than they held under the MDD.

EU MDR sorts devices into four classes:

• Class I: Lowest risk, such as basic reusable instruments.
• Class IIa: Low to moderate risk, such as many short-term devices.
• Class IIb: Moderate to high risk, such as certain longer-term devices.
• Class III: Highest risk, such as implantable and life-sustaining devices.

Your class drives the rest of your work, including the evidence you need and whether a Notified Body must review your device. A device that sat in one FDA class may fall into a different EU MDR class, so confirm your classification early. We help you assign and justify the right class from the start.

What Technical Documentation Does EU MDR Require?

Under the MDD, technical files were often lighter. EU MDR demands a complete, structured technical documentation package that fully describes your device.

Your file must cover:

• Device description and intended purpose
• Design and manufacturing information
• Risk management records aligned with ISO 14971
• Verification and validation data
• Labeling and instructions for use

Reviewers expect this documentation to be thorough, current, and easy to follow. Gaps here rank among the most common reasons submissions stall. MedLaunch helps you prepare and review your full technical file, so it holds up under scrutiny.

Why Is the Clinical Evaluation Report So Important?

The Clinical Evaluation Report (CER) is where EU MDR raised the bar most sharply. This report proves your device is safe and performs as intended, backed by clinical evidence.

Compared to the MDD, EU MDR expects:

• Stronger clinical data, with less reliance on comparisons to similar devices.
• A continuous process, since your CER must stay current across the device’s life.
• Clear links between your clinical evidence, your risk analysis, and your claims.

For many Indiana developers, the CER is the single largest workstream. Starting early pays off, and we help you build the clinical evidence that supports your device.

How Does Post-Market Surveillance Work Under EU MDR?

EU MDR treats your work after launch as seriously as the work before it. Post-Market Surveillance (PMS) is your system for tracking real-world performance and acting on what you learn.

A compliant PMS system includes:

• A PMS plan that defines how you collect and review data.
• Periodic Safety Update Reports (PSURs) for higher-risk devices.
• A feedback loop that ties field data back to your risk management and technical file.

This ongoing duty keeps your device compliant long after it reaches European patients. MedLaunch helps you set up robust surveillance systems that respond quickly to market and regulatory changes.

Your Step-by-Step CE Marking Roadmap

CE marking under EU MDR follows a clear sequence. Here is the path, broken into manageable steps.

1. Confirm your device qualifies. Verify your product meets the EU definition of a medical device.
2. Determine your risk class. Classify your device (Class I, IIa, IIb, or III) under EU MDR rules.
3. Appoint an Authorized Representative. As an Indiana-based manufacturer, you must name an EU-based representative.
4. Build your quality management system. Put an ISO 13485 aligned QMS in place to support design, production, and monitoring.
5. Compile your technical documentation. Assemble a complete technical file, including your risk management records.
6. Prepare your Clinical Evaluation Report. Gather and document the clinical evidence that supports your device.
7. Engage a Notified Body. For most classes above Class I, an accredited Notified Body reviews and audits your submission.
8. Set up Post-Market Surveillance. Establish your PMS system before you launch, not after.
9. Register in EUDAMED and apply UDI. Register your device and assign Unique Device Identifiers as required.
10. Affix the CE mark and launch. Once certified, you can legally sell your device across the European Union.

Each step builds on the last. As your partner, MedLaunch keeps the sequence on track and helps you avoid costly rework.

What Are the EU MDR Transition Timelines?

EU MDR became fully applicable on May 26, 2021, and it now governs all new devices entering the European market. Extended transition dates apply to certain legacy devices that hold valid MDD certificates.

• New devices: Must meet EU MDR requirements today.
• Legacy devices: Follow extended transition dates that run through 2027 and 2028, depending on risk class and certificate status.

If you sell a device previously approved under the MDD, plan your transition early. The work often includes stronger clinical evidence, updated technical documentation, and a compliant PMS system. We help you time each step so you stay on the market without a gap.

Schedule Your Indiana EU MDR Consultation

Ready to bring your device to the European market? MedLaunch partners with Indiana developers at every stage, turning a demanding regulation into a clear plan. Our support includes:

• Gap Analysis and Strategic Planning: We compare your current systems against EU MDR requirements, then build a customized roadmap that closes gaps and fits your goals.
• Technical Documentation Support: We help you prepare and review your full technical file, including clinical evaluations, risk assessments, and quality records.
• Post-Market Surveillance Setup: We design PMS systems that keep you compliant and ready to respond to field data.
• Training and Organizational Support: We equip your team with practical knowledge of EU MDR through targeted training and ongoing guidance.

Contact MedLaunch to schedule a consultation or a regulatory audit. We will review your current position, flag the gaps that matter most, and map a clear path to CE marking and a launch in Europe.